Published in Lab Law Weekly, February 16th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Helix BioMedix.
Report 1: Helix BioMedix, Inc., (HXBM.OB), a developer of bioactive peptides, announced financial results for the 3- and 9-month periods ended September 30, 2006 with a third quarter net loss of $870,507, or $0.04 net loss per share, compared to a net loss of $797,951, or $0.04 net loss per share, for the comparable period in 2005.
Revenue for the 3-month period ended September 30, 2006 was $18,841, derived from licensing revenue and the sale of peptides....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.